冬凌草:一种有效的抗肿瘤草药疗法——植物学、植物化学、临床应用及见解
Rabdosia rubescens (Hemsl.) H. Hara: A potent anti-tumor herbal remedy - Botany, phytochemistry, and clinical applications and insights.
作者信息
Gao Shiyong, Li Jianwen, Wang Weiya, Wang Yue, Shan Yanmin, Tan Huixin
机构信息
Drug Engineering and Technology Research Center, Harbin University of Commerce, Harbin, 150076, Heilongjiang, China; Heilongjiang Provincial Key Laboratory of Tumor Prevention and Antitumor Drugs, Harbin, 150076, Heilongjiang, China.
Department of Pharmacy, Fourth Affiliated Hospital of Harbin Medicine University, Harbin, 150001, Heilongjiang, China.
出版信息
J Ethnopharmacol. 2025 Jan 31;340:119200. doi: 10.1016/j.jep.2024.119200. Epub 2024 Dec 3.
ETHNOPHARMACOLOGICAL RELEVANCE
Traditional Chinese herbal medicine has unique advantages as anti-cancer drugs and adjuvant therapies. Rabdosia rubescens (Hemsl.) H. Hara (R. rubescens) is a traditional medicinal plant known for its anti-inflammatory, antioxidant, antibacterial, anti-angiogenic and antitumor properties. The antitumor activity of R. rubescens is widely recognized among the folk communities in Henan Province, China.
AIM OF THE STUDY
This study reviews the botany, ethnopharmacology, phytochemistry, anti-tumor active ingredients, mechanisms, and clinical applications of R. rubescens, aiming to provide a comprehensive understanding for its use as an anti-cancer drug and adjuvant therapy.
MATERIALS AND METHODS
We systematically searched the literature in PubMed, Web of Science, and CNKI using the following keywords: "Rabdosia rubescens", "Isodon rubescens", "traditional application", "anti-tumor", "phytochemistry", "anti-tumor active compounds", "oridonin" and "clinical application". The search covered publications from 1997 to 2024. Inclusion criteria included original studies or reviews focusing on the anti-tumor properties of R. rubescens or its active components. Exclusion criteria included studies related to non-R. rubescens applications.
RESULTS
R. rubescens is a perennial herbaceous plant in the family Lamiaceae, mainly found in central and southern China. Historically, it has been used to treat conditions such as sore throat, cough, and excess phlegm. The plant contains various compounds, including diterpenes, triterpenes, steroids, flavonoids, phenolic acids, essential oils, amino acids, alkaloids, and polysaccharides, with diterpenes, triterpenes, flavonoids, and phenolic acids being the most active. This review identifies 50 compounds with anti-tumor properties, comprising 34 diterpenes, 2 triterpenes, 7 flavonoids, and 7 phenolic acids. Notably, besides oridonin and ponicidin, the ent-kaurane diterpenoids (20S)-11β,14β,20-trihydroxy-7α,20-epoxy-ent-kaur-16-en15-one and (20S)-11β,14β-dihydroxy-20-ethoxy7α,20-epoxy-ent-kaur-16-en-15-one demonstrate significant anti-tumor activity, attributed to their carbonyl group at C-15, hydroxyl group at C-1, and OEt group at C-20. Mechanistically, R. rubescens combats tumors by blocking the tumor cell cycle, promoting apoptosis, inhibiting cell migration and angiogenesis, inducing ferroptosis, reversing drug resistance, and enhancing radiosensitivity in tumor cells. Clinically, R. rubescens is available in various forms, including tablets, drops, syrups, capsules, and lozenges, and is primarily used for tonsillitis, pharyngitis, and stomatitis. According to the 2020 edition of the Pharmacopoeia of China, R. rubescens tablets are recognized as an adjuvant therapy for cancer. Clinical studies indicate that R. rubescens syrup, tablets, and thermal therapy can enhance cancer patient survival rates and lower tumor recurrence rates.
CONCLUSIONS
Given its traditional and modern uses, active anti-tumor components, and mechanisms, R. rubescens is a promising resource in traditional Chinese medicine for anti-tumor therapy. To realize its full potential, future research should explore additional active anti-tumor compounds beyond oridonin and ponicidin. For these key components, studies should focus on structural modifications to identify new active molecules and essential anti-tumor structures. Clinically, it is important to investigate how R. rubescens interacts with other Chinese herbs in anti-tumor formulations to enhance treatment efficacy and guide appropriate clinical use. Furthermore, future studies should undergo ethical review and include larger-scale randomized controlled trials to validate the efficacy of R. rubescens in treating tumors, thereby promoting its role as an anti-tumor traditional Chinese medicine.
民族药理学相关性
传统中药作为抗癌药物和辅助治疗手段具有独特优势。冬凌草是一种传统药用植物,以其抗炎、抗氧化、抗菌、抗血管生成和抗肿瘤特性而闻名。在中国河南省的民间社区,冬凌草的抗肿瘤活性得到广泛认可。
研究目的
本研究综述了冬凌草的植物学、民族药理学、植物化学、抗肿瘤活性成分、作用机制及临床应用,旨在全面了解其作为抗癌药物和辅助治疗的用途。
材料与方法
我们使用以下关键词在PubMed、Web of Science和中国知网系统检索文献:“冬凌草”、“碎米桠”、“传统应用”、“抗肿瘤”、“植物化学”、“抗肿瘤活性化合物”、“冬凌草甲素”和“临床应用”。检索涵盖1997年至2024年的出版物。纳入标准包括聚焦冬凌草或其活性成分抗肿瘤特性的原始研究或综述。排除标准包括与非冬凌草应用相关的研究。
结果
冬凌草是唇形科多年生草本植物,主要分布于中国中部和南部。历史上,它被用于治疗喉咙痛、咳嗽和痰多等病症。该植物含有多种化合物,包括二萜类、三萜类、甾体类、黄酮类、酚酸类、精油、氨基酸、生物碱和多糖,其中二萜类、三萜类、黄酮类和酚酸类最为活跃。本综述鉴定出50种具有抗肿瘤特性的化合物,包括34种二萜类、2种三萜类、7种黄酮类和7种酚酸类。值得注意的是,除冬凌草甲素和冬凌草乙素外,对映贝壳杉烷二萜类化合物(20S)-11β,14β,20-三羟基-7α,20-环氧-对映贝壳杉-16-烯-15-酮和(20S)-11β,14β-二羟基-20-乙氧基-7α,20-环氧-对映贝壳杉-16-烯-15-酮也表现出显著的抗肿瘤活性,这归因于它们在C-15位的羰基、C-1位的羟基和C-20位的乙氧基。在作用机制上,冬凌草通过阻断肿瘤细胞周期、促进细胞凋亡、抑制细胞迁移和血管生成、诱导铁死亡、逆转耐药性以及增强肿瘤细胞的放射敏感性来对抗肿瘤。在临床上,冬凌草有多种剂型,包括片剂、滴剂、糖浆剂、胶囊剂和含片,主要用于治疗扁桃体炎、咽炎和口腔炎。根据《中国药典》2020年版,冬凌草片被认定为癌症的辅助治疗药物。临床研究表明,冬凌草糖浆、片剂和热疗可提高癌症患者的生存率并降低肿瘤复发率。
结论
鉴于冬凌草的传统和现代用途、活性抗肿瘤成分及作用机制,它是中药中一种有前途的抗肿瘤治疗资源。为充分发挥其潜力,未来研究应探索除冬凌草甲素和冬凌草乙素之外的其他活性抗肿瘤化合物。对于这些关键成分,研究应集中在结构修饰上,以确定新的活性分子和关键抗肿瘤结构。在临床上,研究冬凌草在抗肿瘤配方中与其他中药如何相互作用以提高治疗效果并指导合理临床应用非常重要。此外,未来研究应经过伦理审查并纳入更大规模的随机对照试验,以验证冬凌草治疗肿瘤的疗效,从而提升其作为抗肿瘤中药的作用。